Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion
| Autor: | Günther Weigert, Ursula Schmidt-Erfurth, Katharina Eibenberger, Wolf Bühl, Roman Dunavölgyi, Stefan Sacu, Michael Georgopoulos, Sandra Rezar-Dreindl, Andreas Pollreisz, Christoph Krall, Maria-Elisabeth Kroh |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Time Factors Visual Acuity Dexamethasone Aqueous Humor Angiopoietin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Central retinal vein occlusion Ophthalmology Retinal Vein Occlusion medicine Dexamethasone Intravitreal Implant Humans Prospective Studies Glucocorticoids Aged Drug Implants Aqueous humour business.industry Retinal General Medicine medicine.disease eye diseases Vascular endothelial growth factor Treatment Outcome 030104 developmental biology chemistry Anesthesia Intravitreal Injections 030221 ophthalmology & optometry Cytokines Branch retinal vein occlusion Female Chemokines business Tomography Optical Coherence Follow-Up Studies medicine.drug |
| Zdroj: | Acta Ophthalmologica. 95:e119-e127 |
| ISSN: | 1755-375X |
| DOI: | 10.1111/aos.13152 |
| Popis: | Purpose To investigate the influence of intravitreal dexamethasone implant on inflammatory and angiogenic cytokine levels in the aqueous of patients with retinal vein occlusion (RVO). Methods Forty eyes of 40 consecutive patients with macular oedema (ME) due to branch and central retinal vein occlusion (BRVO/CRVO) were treated with an intravitreal dexamethasone implant (Ozurdex®) at baseline and evaluated until month 6. Retreatment was performed in case of recurrent ME earliest 4 months after the baseline treatment. Aqueous humour samples were taken at baseline, months 1, 3, 6 and at the time of each retreatment. Concentrations of 29 different cytokines were measured by Luminex® bead assays. The control group comprised healthy patients undergoing cataract surgery. Results At baseline concentrations of interleukin (IL)-8, angiopoietin (ANG)-2 and intercellular adhesion molecule (ICAM)-1 were highly elevated in patients with CRVO compared with controls (p = 0.006; p = 0.02; p = 0.03). Vascular endothelial growth factor (VEGF) concentrations were upregulated in patients with BRVO and CRVO (p = 0.003; p = 0.001). Retreatment with a dexamethasone implant was necessary after 4 months in 14/8 (BRVO/CRVO) patients, 5 months in 5/3 patients and 6 months in one patient (BRVO). After the initial treatment, macrophage chemo-attractant protein (MCP)-1 and IL17-E concentrations decreased in BRVO (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|